Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers

April 2022 in “ The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology ”

Emma Guttman‐Yassky, Ana B. Pavel, Aisleen Diaz, Ning Zhang, Ester Del Duca, Yeriel Estrada, Brett King, Anindita Banerjee, Christopher Banfield, Lori Ann Cox, Martin E. Dowty, Karen Page, Michael S. Vincent, Weidong Zhang, Linda Zhu, Elena Peeva

ritlecitinib brepocitinib alopecia areata JAK inhibitors scalp biomarkers lesional scalp transcriptome Severity of Alopecia Tool SALT scores TH1 markers hair keratin expression

TLDR Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

In a phase 2a randomized, double-blind, placebo-controlled trial involving 46 patients with alopecia areata (AA), ritlecitinib and brepocitinib significantly improved scalp biomarkers and reduced immune abnormalities. Ritlecitinib showed a more gradual improvement by week 24, while brepocitinib showed earlier changes by week 12. Both treatments led to significant reductions in inflammatory T cells and key inflammatory gene subsets, with clinical improvements measured by reductions in SALT scores. Patients with shorter episodes of active hair loss responded better to treatment. The study suggests that these JAK inhibitors could be effective therapeutic options for AA, but larger, long-term trials are needed to further assess their efficacy and safety.

View this study on jacionline.org →

Discuss this study in the Community →

Cited in this study

28 / 28 results

research Combination Tofacitinib and Oral Minoxidil Treatment for Severe Alopecia Areata

23 citations , September 2021 in “Journal of The American Academy of Dermatology”

Tofacitinib and oral minoxidil together effectively regrow hair in severe alopecia areata patients.

research Experience with Oral Tofacitinib in Severe Alopecia Areata with Different Clinical Responses

11 citations , February 2021 in “Journal of Cosmetic Dermatology”

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

research An Excellent Response to Tofacitinib in a Brazilian Adolescent Patient with Alopecia Areata: A Case Report and Review of the Literature

11 citations , November 2019 in “Clinical Case Reports”

A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.

research Experience with Oral Tofacitinib in Adolescents and Adults with Alopecia Areata

9 citations , October 2019 in “Dermatologic Therapy”

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

research Targeting the Janus Kinase Family in Autoimmune Skin Diseases

124 citations , October 2019 in “Frontiers in Immunology”

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

research Treatment of Severe Alopecia Areata with Baricitinib

25 citations , October 2019 in “JAAD Case Reports”

Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.

research Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases

88 citations , August 2019 in “Frontiers in immunology”

Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.

research Alopecia Areata Is Characterized by Dysregulation in Systemic Type 17 and Type 2 Cytokines, Which May Contribute to Disease-Associated Psychological Morbidity

57 citations , July 2019 in “British journal of dermatology/British journal of dermatology, Supplement”

Alopecia areata involves immune system imbalances that may lead to depression and anxiety.

research Janus Kinase Inhibitors: An Innovative Treatment for Alopecia Areata

11 citations , June 2019 in “Journal of dermatology”

New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.

research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study

66 citations , December 2018 in “Dermatology”

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

research High-Throughput T Cell Receptor Sequencing Identifies Clonally Expanded CD8+ T Cell Populations in Alopecia Areata

46 citations , October 2018 in “JCI insight”

CD8+ T cells are involved in alopecia areata and may cause disease relapse.

research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

130 citations , July 2018 in “Journal of Investigative Dermatology”

Tofacitinib may help treat severe hair loss, but more research is needed.

research Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata

53 citations , July 2018 in “Drug design, development and therapy”

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.

research Alopecia Areata: Overview and Insights from January 2018

290 citations , January 2018 in “Journal of The American Academy of Dermatology”

Alopecia areata is an autoimmune condition causing hair loss, influenced by genetics, stress, and diet, and may be prevented by a high soy oil diet.

research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients

24 citations , January 2018 in “International Journal of Trichology”

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

$Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series$

research Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series

44 citations , November 2017 in “Journal of the American Academy of Dermatology”

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

research Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient

22 citations , September 2017 in “Skin appendage disorders”

Ruxolitinib helped a man regrow his beard after years of hair loss.

research The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm

77 citations , June 2017 in “Advances in Therapy”

New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.

research Alopecia Areata: What’s New in Epidemiology, Pathogenesis, Diagnosis, and Therapeutic Options?

56 citations , April 2017 in “Journal of dermatological science”

New insights into the causes and treatments for the autoimmune hair loss condition Alopecia areata have been made.

research Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis

16 citations , January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)”

A patient with complete hair loss regrew all her hair using tofacitinib.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , January 2017 in “Journal of The American Academy of Dermatology”

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

222 citations , September 2016 in “JCI insight”

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

research Treatment of an Alopecia Areata Patient with Tofacitinib Results in Regrowth of Hair and Changes in Serum and Skin Biomarkers

70 citations , July 2016 in “Experimental Dermatology”

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

research Biomarkers of Alopecia Areata Disease Activity and Response to Corticosteroid Treatment

65 citations , April 2016 in “Experimental dermatology”

Corticosteroid treatment reduces inflammation and alters hair keratins in alopecia areata.

research Extensive Alopecia Areata Is Reversed by IL-12/IL-23p40 Cytokine Antagonism

68 citations , January 2016 in “The Journal of Allergy and Clinical Immunology”

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

184 citations , April 2015 in “EBioMedicine”

A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations , August 2014 in “Nature medicine”

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

research Alopecia Areata: An Autoimmune Disease Causing Hair Loss

421 citations , April 2012 in “The New England Journal of Medicine”

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

3 / 3 results

research Alopecia Areata: A Multifactorial Autoimmune Condition

148 citations , March 2019 in “Journal of autoimmunity”

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

research Linear Alopecia Areata

4 citations , November 2018 in “JAAD case reports”

Alopecia areata can sometimes appear as a straight line of hair loss instead of round patches.

research Treating Resistant Cases of Alopecia Universalis

May 2018 in “Journal of cosmetology & trichology”

Combining platelet-rich plasma therapy with prostaglandin-F eye drops can significantly regrow hair in alopecia universalis.